Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Prostatic Neoplasms 15Breast Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Glioblastoma 7Esophageal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Burkitt Lymphoma 7Uterine Cervical Neoplasms 6Rhabdomyosarcoma 6Esophageal Squamous Cell Carcinoma 5Squamous Cell Carcinoma of Head and Neck 4Urinary Bladder Neoplasms 3Sarcoma 3Rhabdomyosarcoma, Embryonal 3Rectal Neoplasms 3Neoplasm Metastasis 3Medulloblastoma 3Lymphoma, Follicular 3Lung Neoplasms 3Hodgkin Disease 3Head and Neck Neoplasms 3Gliosarcoma 3Brain Neoplasms 3Adenocarcinoma of Lung 3Vaginal Neoplasms 2Rhabdomyosarcoma, Alveolar 2Prostate Adenocarcinoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Neuroblastoma 2

Interventions

Cytarabine 4Thioguanine 3pegaspargase 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2azathiopurine 2auricularum 2asparaginase erwinia chrysanthemi recombinant 2Vincristine 2Methotrexate 2Mercaptopurine 2Leucovorin 2Etoposide 2Doxorubicin 2Dexamethasone 2Daunorubicin 2Cyclophosphamide 2Calcium Dobesilate 2Asparaginase 2prednylidene 1deltacortene 1blinatumomab 1Radiotherapy 1Radiation 1Prednisone 1Prednisolone 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Mitoxantrone 1Methylprednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Down Syndrome × Radiation × Clear all
NCT03914625 2026-05-27

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
6,720 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Down Syndrome, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡